Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Dr. Namandje N. BumpusIndependent Director | -3,96k | 12,60k | Automatic Disposition | 3,18 | 14,84k | -21,07% |
| 2026-06-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -5,40k | 17,00k | Sale to Issuer | 3,15 | 291,66k | -1,82% |
| 2026-06-05 | Dr. Najat KhanCEO, President & Director | -23,59k | 84,46k | Automatic Disposition | 3,58 | 108,54k | -17,85% |
| 2026-06-05 | Dr. Christopher C. GibsonInsider | -40,00k | 144,80k | Derivative Exercise and Sale | 3,62 | 300,44k | - |
| 2026-06-03 | Dr. Namandje N. BumpusIndependent Director | -4,39k | 15,53k | Automatic Disposition | 3,54 | 43,17k | -9,22% |
| 2026-06-02 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 110,40k | Automatic Disposition | 3,68 | 6,15M | -0,49% |
| 2026-05-22 | Dr. Christopher C. GibsonInsider | -40,00k | 123,20k | Derivative Exercise and Sale | 3,08 | 300,44k | - |
| 2026-05-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -25,02k | 76,05k | Sale to Issuer | 3,04 | 285,58k | -8,05% |
| 2026-05-15 | Dr. Christopher C. GibsonInsider | -22,82k | 69,38k | Sale to Issuer | 3,04 | 300,44k | -7,06% |
| 2026-05-15 | Dr. David HallettChief Scientific Officer | -26,66k | 81,04k | Sale to Issuer | 3,04 | 406,65k | -6,15% |
| 2026-05-15 | Dr. Najat KhanCEO, President & Director | -62,70k | 190,61k | Sale to Issuer | 3,04 | 132,13k | -32,18% |
| 2026-05-07 | Dr. Christopher C. GibsonInsider | -60,00k | 134,80k | Derivative Exercise and Sale | 3,37 | 244,17k | - |
| 2026-05-05 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 105,60k | Automatic Disposition | 3,52 | 6,18M | -0,48% |
| 2026-04-22 | Dr. Christopher C. GibsonInsider | -40,00k | 144,40k | Derivative Exercise and Sale | 3,61 | 244,17k | - |
| 2026-04-06 | Mr. Ben R. TaylorCFO & President of Recursion UK | -48,03k | 149,37k | Sale to Issuer | 3,11 | 257,37k | -15,73% |
| 2026-04-07 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 93,00k | Automatic Disposition | 3,10 | 6,21M | -0,48% |
| 2026-04-07 | Dr. Christopher C. GibsonInsider | -40,00k | 124,00k | Derivative Exercise and Sale | 3,10 | 244,17k | - |
| 2026-03-23 | Dr. Christopher C. GibsonInsider | -40,00k | 130,00k | Derivative Exercise and Sale | 3,25 | 244,17k | - |
| 2026-03-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,96k | 26,97k | Automatic Disposition | 3,39 | 203,21k | -3,77% |
| 2026-03-16 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,08k | 24,20k | Sale to Issuer | 3,42 | 203,21k | -3,36% |
| 2026-03-09 | Dr. Najat KhanCEO, President & Director | -28,30k | 94,66k | Automatic Disposition | 3,35 | 40,73k | -40,99% |
| 2026-03-09 | Dr. Christopher C. GibsonInsider | -20,00k | 0,00 | Derivative Exercise and Sale | - | 244,17k | - |
| 2026-03-03 | Dr. Blake C. BorgesonIndependent Director | -170,00k | 588,20k | Verkauf | 3,46 | 6,24M | -2,65% |
| 2026-02-17 | Dr. David HallettChief Scientific Officer | -11,91k | 41,56k | Sale to Issuer | 3,49 | 382,79k | -3,02% |
| 2026-02-18 | Mr. Ben R. TaylorCFO & President of Recursion UK | -13,43k | 41,35k | Automatic Disposition | 3,08 | 203,23k | -6,20% |
| 2026-02-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 41,56k | Sale to Issuer | 3,49 | 203,23k | -5,54% |
| 2026-02-19 | Dr. Christopher C. GibsonInsider | -40,00k | 138,40k | Derivative Exercise and Sale | 3,46 | 244,17k | - |
| 2026-02-17 | Dr. Christopher C. GibsonInsider | -27,27k | 95,15k | Sale to Issuer | 3,49 | 244,17k | -10,04% |
| 2026-02-17 | Dr. Najat KhanCEO, President & Director | -14,28k | 49,84k | Sale to Issuer | 3,49 | 69,03k | -17,14% |
| 2026-02-06 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,40k | 45,37k | Sale to Issuer | 3,98 | 203,23k | -5,31% |
| 2026-02-06 | Dr. David HallettChief Scientific Officer | -11,40k | 45,37k | Sale to Issuer | 3,98 | 300,78k | -3,65% |
| 2026-02-06 | Dr. Najat KhanCEO, President & Director | -10,36k | 41,25k | Sale to Issuer | 3,98 | 33,81k | -23,46% |
| 2026-02-03 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 924,00k | Automatic Disposition | 4,20 | 6,41M | -3,32% |
| 2026-02-04 | Dr. Christopher C. GibsonInsider | -40,00k | 164,80k | Derivative Exercise and Sale | 4,12 | 179,33k | - |
| 2026-02-06 | Dr. Christopher C. GibsonInsider | -10,36k | 36,90k | Sale to Issuer | 3,56 | 179,33k | -5,46% |
| 2026-01-20 | Dr. Christopher C. GibsonInsider | -40,00k | 178,80k | Derivative Exercise and Sale | 4,47 | 159,35k | - |
| 2026-01-06 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 959,20k | Automatic Disposition | 4,36 | 6,63M | -3,21% |
| 2026-01-05 | Dr. Christopher C. GibsonInsider | -60,00k | 170,00k | Derivative Exercise and Sale | 4,25 | 159,35k | - |
| 2025-12-29 | Mr. Ben R. TaylorCFO & President of Recursion UK | -21,38k | 89,38k | Automatic Disposition | 4,18 | 190,38k | -10,10% |
| 2025-12-22 | Dr. Najat KhanCEO, President & Director | -124,40k | 548,59k | Automatic Disposition | 4,41 | 13,83k | -90,00% |
| 2025-12-18 | Mubadala Investment Company PJSCUnternehmen | -12,99M | 56,59M | Verkauf | 4,24 - 4,58 | 0,00 | -100,00% |
| 2025-12-19 | Dr. Christopher C. GibsonInsider | -40,00k | 180,00k | Derivative Exercise and Sale | 4,50 | 159,35k | - |
| 2025-12-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 30,56k | Sale to Issuer | 4,33 | 211,76k | -3,23% |
| 2025-12-04 | Dr. Christopher C. GibsonInsider | -60,00k | 185,20k | Derivative Exercise and Sale | 4,63 | 159,35k | - |
| 2025-12-02 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 961,40k | Automatic Disposition | 4,37 | 6,85M | -3,11% |
| 2025-11-25 | Mr. Ben R. TaylorCFO & President of Recursion UK | -2,27k | 9,15k | Sale to Issuer | 4,03 | 203,81k | -1,10% |
| 2025-11-17 | Dr. Najat KhanCEO, President & Director | -17,58k | 72,80k | Sale to Issuer | 4,14 | 138,23k | -11,29% |
| 2025-11-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 49,30k | Sale to Issuer | 4,14 | 201,25k | -5,59% |
| 2025-11-19 | Dr. Christopher C. GibsonInsider | -40,00k | 166,40k | Derivative Exercise and Sale | 4,16 | 159,35k | - |
| 2025-11-17 | Dr. Christopher C. GibsonInsider | -40,39k | 167,21k | Sale to Issuer | 4,14 | 159,35k | -20,22% |
| 2025-11-04 | Dr. Christopher C. GibsonInsider | -60,00k | 208,40k | Derivative Exercise and Sale | 5,21 | 107,63k | - |
| 2025-10-23 | Dr. Christopher C. GibsonInsider | -100,00k | 570,00k | Derivative Exercise and Sale | 5,70 | 107,63k | - |
| 2025-10-10 | Dr. Christopher C. GibsonInsider | -120,00k | 604,00k | Derivative Exercise and Sale | 6,04 | 100,66k | - |
| 2025-09-25 | Dr. Christopher C. GibsonInsider | -100,00k | 476,00k | Derivative Exercise and Sale | 4,76 | 107,63k | - |
| 2025-09-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 34,09k | Sale to Issuer | 4,83 | 187,82k | -3,62% |
| 2025-09-10 | Dr. Christopher C. GibsonInsider | -120,00k | 471,00k | Derivative Exercise and Sale | 4,71 | 107,63k | - |
| 2025-08-26 | Dr. Christopher C. GibsonInsider | -100,00k | 484,00k | Derivative Exercise and Sale | 4,84 | 107,63k | - |
| 2025-08-18 | Dr. Najat KhanCEO, President & Director | -36,60k | 202,17k | Verkauf | 5,52 | 111,62k | -24,69% |
| 2025-08-15 | Dr. Najat KhanCEO, President & Director | -3,79k | 21,37k | Sale to Issuer | 5,64 | 111,62k | -3,28% |
| 2025-08-15 | Dr. Christopher C. GibsonInsider | -40,39k | 227,80k | Sale to Issuer | 5,64 | 107,63k | -27,29% |
| 2025-08-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 67,16k | Sale to Issuer | 5,64 | 179,86k | -6,21% |
| 2025-08-11 | Dr. Christopher C. GibsonInsider | -541,54k | 2,86M | Derivative Exercise and Sale | 5,28 | 55,91k | - |
| 2025-08-11 | Dr. Christopher C. GibsonInsider | -76,63k | 404,63k | Automatic Disposition | 5,28 | 55,91k | -57,82% |
| 2025-08-11 | Dr. Christopher C. GibsonInsider | -10,00k | 0,00 | Other Disposition | - | 55,91k | -15,17% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
